Tart Cherry Juice for the Prevention of Peripheral Neuropathy in Patients Receiving Paclitaxel for Stage I-IV Invasive Breast or Ovarian Cancer

Inclusion Criteria

• Histologically confirmed invasive breast or ovarian cancer (stage I, II, III, or IV) as per American Joint Committee on Cancer (AJCC) 8th Edition, 2018 Staging Criteria
• Must be planning to receive paclitaxel weekly for 12 weeks (12 weeks total) as part of neoadjuvant, adjuvant, or metastatic cancer treatment * Concurrent biologic therapy (e.g., trastuzumab and pertuzumab) is allowed * Currently receiving hormone therapy, bisphosphonates, denosumab or gonadotrophin releasing hormone (LHRH)-agonists is allowed * Concurrent use of immune checkpoint inhibitor therapy is allowed * (Neo)adjuvant chemotherapy with doxorubicin and cyclophosphamide is allowed * Concurrent use of carboplatin with weekly paclitaxel in the study is allowed
• May participate concurrently in other cancer trials
• Must be able to complete questionnaires in English or Spanish
• Age >= 18 years old at the time of consent
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1 (Karnofsky scale >= 70%)
• Ability to understand and the willingness to sign a written informed consent document
• Individuals of child-bearing potential must agree to use birth control (e.g., hormonal or barrier method; abstinence, an intrauterine device) prior to study entry, for the duration of study participation (including dose interruptions), and for 3 months after the last dose of tart cherry juice supplement; or be surgically sterilized (e.g., hysterectomy or tubal ligation)
• Patients with known human immunodeficiency virus (HIV) are allowed in the study, but HIV-positive patients must have: * A stable regimen of highly active anti-retroviral therapy (HAART) * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections * A CD4 count above 250 cells/uL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests within the last year
• Stated willingness to not drink any additional tart cherry or any cherry juice while on the study
• Ability and willingness to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria

• Have received any prior therapy with taxanes, vinca alkaloids, eribulin, ixabepilone, or platinum. Doxorubicin is allowed (≥ 2 week washout period required)
• Active or history of peripheral neuropathy, or any chronic diseases associated with peripheral neuropathy such as diabetes mellitus, alcohol use disorder, or systemic lupus erythematosus
• Currently taking anticoagulant medication, known bleeding disorders, or low platelet count (< 75,000/mm^3); daily use of antiplatelet agents such as aspirin (> 81 mg daily), clopidogrel, cilostazol, aspirin dipyridamole, or regular use of higher doses of non-steroidal anti-inflammatory agents as determined by the investigator (such as ibuprofen > 800 mg daily or equivalent)
• Currently taking vitamin E, glutamine, alpha lipoic acid, gabapentin, nortriptyline, amitriptyline or duloxetine. If a patient is taking any of these supplements/medications, they must agree to stop at the time of registration. Multivitamins containing vitamin E are allowed, however vitamin E > 1,000 international units (IU) must be discontinued at the time of registration
• Active or history of kidney disease
• Patients may not use cold therapy gloves for chemotherapy induced neuropathy
• Known allergy to cherries
• Inability to swallow liquid
• Pregnant or breastfeeding individuals (lactating individuals must agree not to breast feed while taking study juice supplementation)
• Any condition that would prohibit the understanding or rendering of informed consent
• Any condition that in the opinion of the investigator would interfere with safety or compliance while on trial